Pasithea Therapeutics (KTTA) EPS (Basic) (2021 - 2024)
Historic EPS (Basic) for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$2.41.
- Pasithea Therapeutics' EPS (Basic) rose 4656.32% to -$2.41 in Q4 2024 from the same period last year, while for Dec 2024 it was -$12.69, marking a year-over-year increase of 31.42%. This contributed to the annual value of -$12.69 for FY2024, which is 39.56% down from last year.
- According to the latest figures from Q4 2024, Pasithea Therapeutics' EPS (Basic) is -$2.41, which was up 4656.32% from -$2.87 recorded in Q3 2024.
- In the past 5 years, Pasithea Therapeutics' EPS (Basic) registered a high of $0.12 during Q4 2021, and its lowest value of -$4.51 during Q4 2023.
- Its 4-year average for EPS (Basic) is -$1.67, with a median of -$1.63 in 2022.
- Per our database at Business Quant, Pasithea Therapeutics' EPS (Basic) soared by 8571.43% in 2022 and then crashed by 2590000.0% in 2023.
- Quarter analysis of 4 years shows Pasithea Therapeutics' EPS (Basic) stood at $0.12 in 2021, then crashed by 802.59% to -$0.84 in 2022, then plummeted by 434.93% to -$4.51 in 2023, then soared by 46.56% to -$2.41 in 2024.
- Its last three reported values are -$2.41 in Q4 2024, -$2.87 for Q3 2024, and -$3.71 during Q2 2024.